Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Brightening of a dark monolayer semiconductor via strong light-matter coupling in a cavity.

Nature communications·2022

Same author

Hybridized Exciton-Photon-Phonon States in a Transition Metal Dichalcogenide van der Waals Heterostructure Microcavity.

Physical review letters·2022

Same author

Spatial coherence of room-temperature monolayer WSe<sub>2</sub> exciton-polaritons in a trap.

Nature communications·2021

Same author

Improving the continuity and coordination of ambulatory care through feedback and facilitated dialogue-a study protocol for a cluster-randomised trial to evaluate the ACD study (Accountable Care in Germany).

Trials·2021

Same author

[Erratum to: Prevalence of dementia of insured persons with and without German citizenship : A study based on statutory health insurance data].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2018

Same author

[Prevalence of dementia of insured persons with and without German citizenship : A study based on statuatory health insurance data].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2018

Search research articles

Related Experiment Videos

First German disease management program for breast cancer.

Christoph Rupprecht¹

¹Allgemeine Ortskrankenkasse Rheinland -Die Gesundheitskasse. christoph.rupprecht@rla.aok.de

Health Care Financing Review

|February 10, 2007

Summary

Germany's first breast cancer disease management program, established in 2002, focuses on patient-centered care. This initiative aims to enhance treatment quality, patient involvement, and surgical outcomes for breast cancer patients.

Related Experiment Videos

Area of Science:

Oncology
Healthcare Management
Public Health

Background:

Germany introduced its first disease management program contract for breast cancer in 2002.
This program was established through an agreement between the Association of Regional Physicians in North-Rhine and statutory health insurance providers.

Purpose of the Study:

To enhance the quality of breast cancer treatment and post-operative care.
To empower patients through timely information and consultation, promoting shared decision-making.
To improve care coordination between inpatient and outpatient settings and increase breast-conserving surgeries.

Main Methods:

Implementation of a patient-centered network of healthcare professionals.
Structured program contract outlining objectives and care pathways.
Focus on integrated care and patient empowerment.

Main Results:

Established a foundational model for breast cancer disease management in Germany.
Aimed to improve multiple facets of patient care, from treatment to recovery.
Focused on increasing the rate of breast-conserving surgeries.

Conclusions:

The program represents a significant step in organized breast cancer care in Germany.
Patient-centered networks are crucial for improving outcomes and patient engagement.
The initiative highlights the importance of integrated care and shared decision-making in oncology.